On Monday, Arcus Biosciences Inc (NYSE: RCUS) was -8.09% drop from the session before settling in for the closing price of $15.70. A 52-week range for RCUS has been $13.49 – $20.31.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 164.80% annually for the last half of the decade. When this article was written, the company’s average yearly earnings per share was at 21.11%. With a float of $48.11 million, this company’s outstanding shares have now reached $75.50 million.
In an organization with 577 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 96.2%, operating margin of -120.91%, and the pretax margin is -102.28%.
Arcus Biosciences Inc (RCUS) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Arcus Biosciences Inc stocks. The insider ownership of Arcus Biosciences Inc is 47.43%, while institutional ownership is 54.43%. The most recent insider transaction that took place on Aug 13 ’24, was worth 20,314. In this transaction Chief Accounting Officer of this company sold 1,357 shares at a rate of $14.97, taking the stock ownership to the 19,070 shares. Before that another transaction happened on Mar 27 ’24, when Company’s Chief Operating Officer sold 11,551 for $17.55, making the entire transaction worth $202,720. This insider now owns 215,253 shares in total.
Arcus Biosciences Inc (RCUS) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 21.11% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 7.80% during the next five years compared to -23.70% drop over the previous five years of trading.
Arcus Biosciences Inc (NYSE: RCUS) Trading Performance Indicators
You can see what Arcus Biosciences Inc (RCUS) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 5.23. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 5.00.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.15, a number that is poised to hit -1.20 in the next quarter and is forecasted to reach -4.26 in one year’s time.
Technical Analysis of Arcus Biosciences Inc (RCUS)
Let’s dig in a bit further. During the last 5-days, its volume was 0.62 million. That was inferior than the volume of 0.74 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 13.38%. Additionally, its Average True Range was 1.07.
During the past 100 days, Arcus Biosciences Inc’s (RCUS) raw stochastic average was set at 16.67%, which indicates a significant increase from 1.73% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 65.30% in the past 14 days, which was higher than the 61.51% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $16.58, while its 200-day Moving Average is $16.40. However, in the short run, Arcus Biosciences Inc’s stock first resistance to watch stands at $15.32. Second resistance stands at $16.22. The third major resistance level sits at $16.70. If the price goes on to break the first support level at $13.94, it is likely to go to the next support level at $13.46. Assuming the price breaks the second support level, the third support level stands at $12.56.
Arcus Biosciences Inc (NYSE: RCUS) Key Stats
There are 91,512K outstanding shares of the company, which has a market capitalization of 1.31 billion. As of now, sales total 117,000 K while income totals -307,000 K. Its latest quarter income was 48,000 K while its last quarter net income were -92,000 K.
